SCHEMBL8196479

SCHEMBL8196479

Clc1ccc2c(c1)C(N1CCN(Cc3ccc4c(c3)OCO4)CC1)=Nc1cc(Cl)c(Cl)cc1N2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 10/20 0.69
DRD1 P21728 8/20 0.69
DRD4 P21917 2/20 0.52
LMNA P02545 2/20 0.51
HTT P42858 1/20 0.50
HTR1A P08908 2/20 0.49
HTR3E A5X5Y0 1/20 0.49
HTR3B O95264 1/20 0.49
HTR3A P46098 1/20 0.49
HTR3D Q70Z44 1/20 0.49
HTR3C Q8WXA8 1/20 0.49
PKM P14618 1/20 0.48
DRD3 P35462 3/20 0.47
DRD5 P21918 1/20 0.47
HRH1 P35367 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8203933 0.91 DRD2 (0.74) DRD2DRD1DRD4LMNAHTR1A
SCHEMBL8204496 0.89 DRD2 (0.77) DRD2DRD1DRD4LMNAHTT
SCHEMBL29623704 0.87 DRD2 (0.90) DRD2DRD1DRD4LMNAHTR1A
SCHEMBL8203868 0.83 DRD2 (0.76) DRD2DRD1DRD4LMNAHTT
SCHEMBL8203911 0.80 DRD2 (0.75) DRD2DRD1DRD4LMNAHTR1A
SCHEMBL8204038 0.80 DRD2 (0.69) DRD2DRD1DRD4LMNAHTR1A
SCHEMBL8994839 0.78 DRD2 (0.67) DRD2DRD1DRD4HTTHTR1A
SCHEMBL9050759 0.77 DRD2 (0.62) DRD2DRD1LMNAHTR1AHTR3E
SCHEMBL8506820 0.77 CHRM1 (0.74) DRD2DRD1DRD4LMNAHTR1A
SCHEMBL8202569 0.76 DRD1 (0.64) DRD2DRD1LMNAHTR1ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6103715-A COMPOUNDS THAT BIND TO THE DOPAMINE D4 RECEPTOR AND THEIR USE AS ANXIOLYTIC AGENTS, TREATMENT FOR SCHIZOPHRENIA, AND DRUG SCREENING; SIDE EFFECT REDUCTIOON ALLELIX BIOPHARMACEUTICALS INC. (CA) 2000-08-15 US disclosed
EP-0736024-A1 N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS Allelix Biopharmaceuticals Inc. (CA) 1996-10-09 EP disclosed
US-5538965-A TREATMENT OF PSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA AND ANXIETY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-07-23 US disclosed
WO-1995017400-A1 N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1995-06-29 WO disclosed